Thrombosis pp 287-297 | Cite as

A Discussion of the Possible Significance of PGI2 in Thrombosis

  • J. Bryan Smith
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 102)


Before discussing the significance of PGI2 in thrombosis, it is appropriate to acknowledge that its discovery is due to the contributions of three groups. First, credit should be given to Pace-Asciak and Wolfe (1) who in 1971 were working together at McGill University in Montreal. They isolated, identified, and described the unique chemical properties of a noval compound, 6(9)-oxyprostaglandin F, which was produced from arachidonic acid by homogenates of rat stomach. Secondly, we would not even be discussing PGI2 today were it not for the discoveries of Moncada, Gryglewski, Vane and others (2,3,4) at the Wellcome Research Laboratories in England. They showed that blood vessels make a prostaglandin, temporarily named PGX, with unique and potent biological properties. Finally, credit is due to Johnson, Morton, and others of The Upjohn Company (5) who collaborated with the Wellcome group and proved that the names 6(9)-oxyprostaglandin F and PGX are synonymous. They suggested the use of the trivial name prostacyclin to describe PGX, and I suspect that PGI2 will continue to be called prostacyclin henceforth.


Endothelial Cell Arachidonic Acid Inhibit Platelet Aggregation Washed Platelet Prostaglandin Endoperoxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pace-Asciak C, Wolfe LS: A novel prostaglandin derivative formed from arachidonic acid by rat stomach homogenates. BIOCHEMISTRY 10: 3657–3664, 1971.PubMedCrossRefGoogle Scholar
  2. 2.
    Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. NATURE 263: 663–665, 1976.PubMedCrossRefGoogle Scholar
  3. 3.
    Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR: Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. PROSTAGLANDINS 12: 685–713, 1976.PubMedGoogle Scholar
  4. 4.
    Moncada S, Gryglewski RJ, Bunting S, Vane JR: A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. PROSTAGLANDINS 12: 715–737, 1976.PubMedGoogle Scholar
  5. 5.
    Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF, Whittaker N, Bunting S, Salmon J, Moncada S, Vane JR: The chemical structure of prostaglandin X (prostacyclin). PROSTAGLANDINS 12: 915–928, 1976.PubMedGoogle Scholar
  6. 6.
    Hamberg M, Samuelsson B: Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. PROC NATL ACAD SCI USA 70: 899–903, 1973.PubMedCrossRefGoogle Scholar
  7. 7.
    Nugteren DH, Hazelhof E: Isolation and properties of intermediates in prostaglandin biosynthesis. BIOCHIM BIOPHYS ACTA 326: 448–461, 1973.PubMedCrossRefGoogle Scholar
  8. 8.
    Hamberg M, Svensson J, Wakabayashi T, Samuelsson B: Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. PROC NATL ACAD SCI USA 71: 345–349, 1974.PubMedCrossRefGoogle Scholar
  9. 9.
    Pace-Asciak C: A new prostaglandin metabolite of arachidonic acid. Formation of 6-keto-PGFlu by the rat stomach. EXPERENTIA 32: 291–292, 1976.CrossRefGoogle Scholar
  10. 10.
    Hamberg M, Samuelsson B: Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. PROC NATL ACAD SCI USA 71: 3400–3404, 1974.PubMedCrossRefGoogle Scholar
  11. 11.
    Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. PROC NATL ACAD SCI USA 72: 2994–2998, 1975.PubMedCrossRefGoogle Scholar
  12. 12.
    Gorman RR, Bunting S, Miller OV: Modulation of human platelet adenylate cyclase by prostacyclin (PGX). PROSTAGLANDINS 13: 377–388, 1977.PubMedGoogle Scholar
  13. 13.
    Tateson JE, Moncada S, Vane JR: Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. PROSTAGLANDINS 13: 389–397, 1977.PubMedGoogle Scholar
  14. 14.
    Saba SR, Mason RG: Studies of an activity from endothelial cells that inhibits platelet aggregation, serotonin release, and clot retraction. THROMB RES 5: 747–757, 1974.PubMedCrossRefGoogle Scholar
  15. 15.
    Weksler BB, Marcus AJ, Jaffe EA: Synthesis of PGI2 (prostacyclin) by cultured human and bovine endothelial cells. PROC NATL ACAD SCI USA (In Press).Google Scholar
  16. 16.
    Harker LA, Joy N, Wall RT, Quadracci L, Striker G: Inhibition of platelet reactivity by endothelial cells (Abstract). THROMB HAEMOSTAS 38: 137, 1977.Google Scholar
  17. 17.
    Wen-Chang C, Murota S: Identification of 6-ketoprostaglandin Fla formed from arachidonic acid in bovine seminal vesicles. BIOCHIM BIOPHYS ACTA 486: 136–144, 1977.CrossRefGoogle Scholar
  18. 18.
    Weiss HJ, Aledort LM, Kochwa S: The effect of salicylates on the hemostatic properties of platelets in man. J CLIN INVEST 47: 2169–2180, 1968.PubMedCrossRefGoogle Scholar
  19. 19.
    Silver MJ, Hoch W, Kocsis JJ, Ingleman CM, Smith JB: Arachidonic acid causes sudden death in rabbits. SCIENCE 183: 1085–1087, 1974.PubMedCrossRefGoogle Scholar
  20. 20.
    Uzunova A, Ramey E, Ramwell PW: Effect of testosterone, sex and age on experimentally induced arterial thrombosis. NATURE 261: 712–713, 1976.PubMedCrossRefGoogle Scholar
  21. 21.
    Uzunova AD, Ramey ER, Ramwell PW: Arachidonate-induced thrombosis in mice: Effect of gender or testosterone and estradiol administration. PROSTAGLANDINS 13: 995–1002, 1977.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1978

Authors and Affiliations

  • J. Bryan Smith
    • 1
  1. 1.Cardeza Foundation and Department of PharmacologyThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations